ArticleRSC advances2021
Dissolving microneedles delivering cancer cell membrane coated nanoparticles for cancer immunotherapy.
Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Recent advances in dissolving microneedles for breast cancer immunotherapy: local delivery and tumor microenvironment remodeling.Frontiers in immunology · 2026Review
- Polymeric Microneedles: Advancing Potential Through Innovative Manufacturing, Polymer Design, and Characterization Techniques.Current pharmaceutical design · 2026Review
- Recent Developments in Nanoparticle-Hydrogel Hybrid Materials for Controlled Release.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.Advanced drug delivery reviews · 2024Review
- Microneedle-Mediated Cell Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Microneedle-enhanced drug delivery: fabrication, characterization, and insights into release and permeation of nanocrystalline imiquimod.Frontiers in drug delivery · 2024Article
- TME-Related Biomimetic Strategies Against Cancer.International journal of nanomedicine · 2024Review
- Advances in Nanotherapy for Targeting Senescent Cells.International journal of nanomedicine · 2024Review
- PEDF-Enriched Extracellular Vesicle for Vessel Normalization to Potentiate Immune Checkpoint Blockade Therapy.Biomaterials research · 2024Article
- Exploiting Unique Features of Microneedles to Modulate Immunity.Advanced materials (Deerfield Beach, Fla.) · 2023Review
- Biomimetic Cell-Derived Nanoparticles: Emerging Platforms for Cancer Immunotherapy.Pharmaceutics · 2023Review
- Review
- Recent progress in cancer cell membrane-based nanoparticles for biomedical applications.Beilstein journal of nanotechnology · 2023Review
- Revolutionizing Therapeutic Delivery with Microneedle Technology for Tumor Treatment.Pharmaceutics · 2022Review
- Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy.Frontiers in oncology · 2022Review
- Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, a variety of tumor vaccines and immune system stimulators such as toll-like receptor (TLR) agonists have been widely investigated for cancer immunotherapy
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.